Stage III EML4-ALK lung adenocarcinoma: brigatinib, surgery, no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EML4-ALK fusion rearrangement

No evidence of disease on PET-CT, with no brain metastases on MRI, after 32 months of adjuvant brigatinib following response and surgery.

PubMed CentralRead more →

Stage III EGFR-mutated lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR L858R; EGFR L861Q

No evidence of disease on PET-CT or brain MRI after 42 months of follow-up following neoadjuvant osimertinib and surgery.

PubMed CentralRead more →

Stage 3C lung cancer: complete remission on immunotherapy and chemotherapy

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: EGFR wild-type; ALK rearrangement not detected; PD-L1 <1%

Complete tumor remission with no recurrence more than 6 months after durvalumab, tremelimumab, carboplatin, and nab-paclitaxel for Stage IIIC driver-negative NSCLC, despite severe immune, infectious, cardiac, renal, and fistula complications that later resolved or stabilized.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma Treated With Complex Lung-Sparing Surgery and Adjuvant Therapy

Patient Info: Anonymized, male, Under 40 | Stage III

Biomarkers: PD-L1 high expression

Follow-up through 3 years after surgery showed no recurrence or metastasis, with stable lung function and unrestricted physical activity.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma: Payton's Survivor Story

Patient Info: Payton Gibbs, Female, Under 40 | Stage III

As of August 2024, Payton described herself as cancer-free after lobectomy and 4 rounds of adjuvant chemotherapy.

The Patient StoryRead more →

BRAF-mutant lung cancer: complete pathologic response after targeted therapy and surgery

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: BRAF ; PD-L1 80%; TMB 1 mutation per megabase; MSS

Pathologic complete response after BRAF/MEK-targeted neoadjuvant therapy and surgery for BRAF V600E lung cancer; no recurrence or metastasis observed as of March 2024.

PubMed CentralRead more →

Stage IIIA ALK-positive lung adenocarcinoma: pathologic complete response to lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: EML4-ALK fusion; ALK-positive; Napsin A-positive; cytokeratin-positive; TTF-1-positive

He remained disease-free 10 months after surgery while continuing planned adjuvant lorlatinib after neoadjuvant lorlatinib produced partial radiographic response and pathologic complete response.

PubMed CentralRead more →

Stage 3 lung cancer: complete response to chemo and immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Tumor markers were normal during mesorectal nodule workup; lung molecular biomarkers were not reported.

No radiologic NSCLC recurrence was detected during 16 months of follow-up after complete response to cisplatin/docetaxel chemoradiation plus 1 year of durvalumab; the suspicious mesorectal nodule proved to be a benign organized thrombus.

PubMed CentralRead more →

Stage IIIA ALK-rearranged NSCLC: pathologic complete response to neoadjuvant brigatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: ALK gene rearrangement; CEA 8.49 ng/mL

He remained disease-free during 13 months of follow-up after neoadjuvant brigatinib reduced Stage IIIA ALK-rearranged NSCLC and curative-intent surgery showed pathologic complete response.

PubMed CentralRead more →

Stage III lung squamous cell cancer treated with immunotherapy, surgery and chemotherapy

Patient Info: Anonymized, male, 50s | Stage III

After surgery and systemic treatment, updated follow-up found no recurrence or metastasis. Tislelizumab remained stopped after recurrent adrenal insufficiency.

PubMed CentralRead more →

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

Stage IIIA EGFR-mutated lung squamous cell carcinoma: pathologic complete response to aumolertinib

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: EGFR exon 19 deletion; p40-positive lung squamous cell carcinoma

At the 1 April 2024 cutoff, she had no recurrence after 20 months of treatment following neoadjuvant aumolertinib, pathologic complete response at surgery, and ongoing adjuvant aumolertinib.

PubMed CentralRead more →

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed CentralRead more →

Radiation pneumonitis during chemoradiotherapy for Stage III squamous lung cancer

Patient Info: Anonymized, Male, 70+ | Stage III

An 88-year-old man with Stage III squamous lung cancer developed radiation pneumonitis during chemoradiotherapy, with symptoms and imaging improving after steroid treatment.

PubMed CentralRead more →

Stage III small cell lung cancer complicated by a tracheomediastinal fistula during chemoradiation

Patient Info: Anonymized, male, 70+ | Stage III

Four months after treatment began, there was no evident cancer recurrence, although the persistent fistula remained under consideration for repair.

PubMed CentralRead more →

Stage III squamous lung cancer complicated by a fatal postoperative bronchopleural fistula

Patient Info: Anonymized, male, 40s | Stage III

He developed a postoperative bronchopleural fistula with pulmonary infection and worsening respiratory failure, and died on December 2, 2020.

PubMed CentralRead more →

Stage III squamous lung cancer with a postoperative bronchopleural fistula successfully repaired

Patient Info: Anonymized, male, 50s | Stage III

After bronchoscopic repair of a postoperative bronchopleural fistula, he was followed for more than 1 year with CT every 3 months and no lung-cancer recurrence.

PubMed CentralRead more →

Stage III squamous lung cancer with a postoperative bronchopleural fistula that resolved with treatment

Patient Info: Anonymized, male, 60s | Stage III

The postoperative bronchopleural fistula resolved after anti-infective treatment, and serial CT scans showed no lung-cancer recurrence during ongoing follow-up.

PubMed CentralRead more →

Stage III lung adenocarcinoma with a postoperative bronchopleural fistula and no recurrence

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: EGFR, ALK, KRAS, RET and ROS1 negative

After treatment of a postoperative bronchopleural fistula, she was followed for more than 1 year with CT every 3 months and no lung-cancer recurrence.

PubMed CentralRead more →

Stage III squamous lung cancer controlled during treatment while a second pancreatic cancer developed

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: KRAS exon 2 mutation

She died in March 2022. Her Stage III lung cancer had remained controlled for about 18 months, while a separate pancreatic cancer developed and progressed.

PubMed CentralRead more →

EGFR-mutated Stage III lung cancer became undetectable during erlotinib plus dendritic-cell vaccination

Patient Info: Anonymized, female, 60s | Stage III

Biomarkers: EGFR mutation; ALK-negative; PD-L1 <1%

CT showed no detectable lung cancer by day 321, and the disappearance was maintained for at least 587 days without recurrence or metastasis.

PubMed CentralRead more →

Stage III small-cell lung cancer had a complete response after chemo-immunotherapy and surgery

Patient Info: Anonymized, female, 50s | Stage III

Surgery showed a pathological complete response, and no recurrence or metastasis was found through 12 months of follow-up.

PubMed CentralRead more →

Lung cancer in a young adult mistaken for recurring pneumonia

Patient Info: Anonymized, Male | Stage III

Biomarkers: KRAS mutation

Two months after discharge, he began carboplatin, pemetrexed and pembrolizumab and had received 2 cycles.

PubMed CentralRead more →

Lung cancer immunotherapy causing sudden heart inflammation and type 1 diabetes

Patient Info: Anonymized, Female | Stage III

Her acute symptoms resolved, cardiac function returned to her baseline ejection fraction of 32% at 1 month and durvalumab remained permanently discontinued while oncology, endocrine and cardiac follow-up continued.

PubMed CentralRead more →